TACE combined with DynaCT-guided MWA in the treatment of high-risk location liver cancers with ≤5 cm tumor size - Takeaways - MDSpire

TACE combined with DynaCT-guided MWA in the treatment of high-risk location liver cancers with ≤5 cm tumor size

  • By

  • Daqian Han

  • Gezhen Wang

  • Fangzheng Li

  • Chao Liang

  • Jiacheng Wang

  • Yangyang Niu

  • Hao Li

  • Shuguang Ju

  • Manzhou Wang

  • Xuhua Duan

  • May 7, 2026

Share

  • 1

    The study evaluated the safety and effectiveness of combining TACE with DynaCT-guided MWA for liver tumors ≤5 cm in high-risk locations.

  • 2

    Fifty-five patients with newly diagnosed liver cancer underwent the combination treatment, achieving a 96.4% objective response rate after one month.

  • 3

    Adverse events were mostly mild, classified as grade 1 or 2, requiring minimal intervention, indicating a favorable safety profile.

  • 4

    The mean overall survival was 41.0 months, and the mean progression-free survival was 31.2 months in the high-risk location group.

  • 5

    The combination treatment demonstrated promising cumulative survival rates of 98.1%, 94.5%, 85.4%, and 74.5% at 6, 12, 24, and 36 months, respectively.

Original Source(s)

TACE combined with DynaCT-guided MWA in the treatment of high-risk location liver cancers with ≤5 cm tumor size

  • by Daqian Han, Gezhen Wang, Fangzheng Li, Chao Liang, Jiacheng Wang, Yangyang Niu, Hao Li, Shuguang Ju, Manzhou Wang, Xuhua Duan

  • May 7, 2026

Related Content

One Pathway for Esophageal Cancer?

Molecular profiling reveals precursor signals in BE-negative esophageal cancer

  • May 7, 2026

  • 2 min
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...